Anti-FHL1 autoantibodies in adult patients with myositis: a longitudinal follow-up analysis
Authors:
- Angeles S Galindo-FeriaAGAngeles S Galindo-Feria
- Marie Wahren-HerleniusMWMarie Wahren-Herlenius
- Ingrid E LundbergILIngrid E Lundberg
- The SweMyoNet ConsortiumTCThe SweMyoNet Consortium
- Aladdin J MohammadAMAladdin J Mohammad
Open Access
- 4 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (3) , 1482-1492
Abstract
To determine prevalence and clinical associations of anti-FHL1 autoantibodies in patients with idiopathic inflammatory myopathies (IIM), and to evaluate autoantibody levels over time. Sera at the time of diagnosis from patients with IIM (n = 449), autoimmune disease controls (DC, n = 130), neuromuscular diseases (NMD, n = 16) and healthy controls (HC, n = 100) were analyzed for anti-FHL1 autoantibodies by Enzyme-Linked ImmunoSorbent Assay (ELISA). Patients with IIM FHL1+ and FHL1- were included in a longitudinal analysis. Serum levels were correlated to disease activity. Autoantibodies to FHL1 were more frequent in patients with IIM (122/449, 27%) compared with DC (Autoimmune DC and NMD, 13/146, 9%, p< 0.001) and HC (3/100,3%, p< 0.001). Anti-FHL1 levels were higher in IIM [median (IQR)=0.62 (0.15–1.04)] in comparison with DC [0.22 (0.08–0.58)], HC [0.35 (0.23–0.47)] and NMD [0.48 (0.36–0.80)] p< 0.001. Anti-FHL1+ patients with IIM were younger at time of diagnosis compared with the anti-FHL1- group (p= 0.05) and were seronegative for other autoantibodies in 25%. In the first follow-up anti-FHL1+ sample 20/33 (60%) positive at baseline had turned negative for anti-FHL1 autoantibodies. Anti-FHL1 autoantibodies rarely appeared after initiating treatment. Anti-FHL1 autoantibody levels correlated with CK (r = 0.62, p= 0.01), disease activity measure MYOACT (n = 14, p= 0.004) and inversely with manual muscle test-8 (r=-0.59, p= 0.02) at baseline. Anti-FHL1 autoantibodies were present in 27% of patients with IIM, of these 25% were negative for other autoantibodies. Other autoimmune diseases had lower frequencies and levels. Anti-FHL1 levels often decreased with immunosuppressive treatment, correlated with disease activity measures at diagnosis and rarely appeared after start of treatment.Keywords
Funding Information
- Swedish Research Council (2020–01378)
- Swedish Rheumatism Association
- King Gustaf V 80 Year Foundation
- Konung Gustaf V: S och Drottning Victorias Frimurarestiftelse
- Region Stockholm
- astra zeneca
This publication has 29 references indexed in Scilit:
- Autoantibodies against four-and-a-half-LIM domain 1 (FHL1) in inflammatory myopathies: results from an Australian single-centre cohortRheumatology, 2022
- 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018Neuromuscular Disorders, 2020
- Autoantibodies in myositisNature Reviews Rheumatology, 2018
- Classification of myositisNature Reviews Rheumatology, 2018
- 224th ENMC International Workshop:Neuromuscular Disorders, 2018
- Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis seraJournal of Immunological Methods, 2016
- Anti-DNA antibodies — quintessential biomarkers of SLENature Reviews Rheumatology, 2015
- 199th ENMC international workshop: FHL1 related myopathies, June 7–9, 2013, Naarden, The NetherlandsNeuromuscular Disorders, 2014
- Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C‐HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF‐36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index‐2 (FI‐2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)Arthritis Care & Research, 2011
- Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage indexArthritis & Rheumatism, 2009